Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × CT103A chimeric antigen receptor × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Cyclophosphamide 33 Paclitaxel 29 Gemcitabine 26 Carboplatin 26 Cisplatin 25 Nivolumab 23 camrelizumab 21 Capecitabine 21 fludarabine 19 apatinib 19 toripalimab 18 Oxaliplatin 17 Immunotherapy, Adoptive 17 pembrolizumab 15 Radiotherapy 15 Bevacizumab 15 Drug Therapy 14 Docetaxel 14 Rituximab 13 tislelizumab 12 Temozolomide 12 Injections 12 Dexamethasone 12 Cetuximab 11 Irinotecan 10 Cytarabine 10 anlotinib 9 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9 130-nm albumin-bound paclitaxel 9 Trastuzumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05066646 2021-11-23

FUMANBA-1

Nanjing IASO Biotechnology Co., Ltd.

Phase 1/2 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡